C4 therapeutics announces strategic discovery research collaboration with merck kgaa, darmstadt, germany, against critical oncogenic proteins

Collaboration focused on two targeted protein degraders from c4t's internal discovery pipeline c4t to receive a $16 million upfront payment; merck kgaa, darmstadt, germany, to cover discovery research costs under the collaboratio n c4t eligible for up to approximately $740 million in discovery, development and commercial milestone payments, in addition to future royalties, across entire collaboration watertown, mass., march 04, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with merck kgaa, darmstadt, germany, which operates its healthcare business as emd serono in the u.s. and canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that c4t has progressed within its internal discovery pipeline.
CCCC Ratings Summary
CCCC Quant Ranking